ビクトリースクエア・テクノロジーズは 2025年第3四半期に売上を倍増し,利益を維持し,健康対策を拡大しました. Victory Square Technologies doubled revenue, stayed profitable, and expanded health initiatives in Q3 2025.

Victory Square Technologiesは,Hydreight Technologiesが年2分の2の売上を倍増させ,連続4分の1の収益を達成し,米国50州全域で準拠した臨床ネットワークを維持し,2025会計年度には110万件以上の製品注文を予測した強力なQ3の業績を報告した. Victory Square Technologies reported strong Q3 2025 results, with Hydreight Technologies doubling revenue year-over-year and achieving its fourth consecutive profitable quarter, maintaining a compliant clinical network across all 50 U.S. states and projecting over 1.1 million product orders for fiscal year 2025. 同社は100万ドル規模のデジタル健康と長寿加速器を立ち上げ,2026年に初めてヒト研究のために口服インスリン錠の開発を進めて100万ドル規模のペットウェルネスベンチャーファンドを立ち上げました. The company launched a $10 million digital health and longevity accelerator, advanced its oral insulin tablet development for first-in-human studies in 2026, and launched a $10 million pet wellness venture fund. 勝利広場は25億円の現金と市場資本で四半期を終結し、米国の医療費の増加に伴う高成長部門に戦略的焦点を掲げた。 Victory Square ended the quarter with $25.91 million in cash and marketable securities, emphasizing its strategic focus on high-growth sectors amid rising U.S. healthcare spending.